Ganaxolone Treatment For Refractory Epilepsy Overview In a meta-analysis conducted to evaluate the use of ganaxolone for refractory epilepsy, researchers collected data from four randomized controlled trials involving a total of 659 patients. The analysis revealed that ganaxolone significantly improved the reduction in mean seizure frequency by ≥50% when compared to a
Author: Nancy Ogbonna
Insulin Therapy for Wound Healing: A Meta-Analysis
Insulin Therapy for Wound Healing: A Meta-Analysis Overview Insulin, known for its affordability and widespread availability, has emerged as a promising agent in the realm of wound healing. This study delved into the potential of local insulin administration to facilitate the recovery of damaged skin among non-diabetic adults. To achieve this, a
PD-1/L1 Inhibitors: Treatment Efficacy In Urothelial Carcinoma
PD-1/L1 Inhibitors: Treatment Efficacy In Urothelial Carcinoma Overview Programmed cell death‐1/ligand 1 (PD-1/PD-L1) inhibitors represent a novel therapeutic approach for advanced urothelial carcinoma, prompting the need for a comparative assessment of their effectiveness and safety in comparison to traditional chemotherapy. To address this, a comprehensive meta-analysis of randomized controlled trials conducted until
Skin Lightening: Topical Approaches To Treatment
Skin Lightening: Topical Approaches To Treatment Overview The recent removal of hydroquinone from over-the-counter skin lightening products has created a demand for modern formulations that effectively address skin pigmentation issues. A successful skin lightening formulation should be non-irritating to prevent post-inflammatory hyperpigmentation, penetrate effectively to reach the epidermal/dermal junction, incorporate anti-inflammatory ingredients,
Encapsulated Papillary Carcinoma Membrane Characteristics
Encapsulated Papillary Carcinoma Membrane Characteristics Overview This study focused on encapsulated papillary carcinoma (EPC), a type of breast carcinoma characterized by a thick fibrous capsule-like structure surrounding the tumor, often interpreted as a thickened basement membrane (BM). The primary objective was to investigate the geometric properties of the EPC capsule and determine
Chemotherapy-Induced Thrombocytopenia in Nasopharyngeal Carcinoma
Chemotherapy-Induced Thrombocytopenia in Nasopharyngeal Carcinoma Overview This study aimed to investigate serious chemotherapy-induced thrombocytopenia (CIT) in nasopharyngeal carcinoma (NPC), focusing on its incidence, consequences, and predictors. The retrospective analysis of NPC patients from 2013 to 2015 revealed a 5.21% incidence of serious chemotherapy-induced thrombocytopenia. Patients experiencing severe thrombocytopenia had notably worse long-term prognoses,
Endocrine Therapy Outcomes In Senior Breast Cancer Patients
Endocrine Therapy Outcomes In Senior Breast Cancer Patients Overview This study investigated the management of early-stage, hormone receptor-positive, and human epidermal growth factor receptor 2 negative (HR+/HER2−) breast cancer in older women aged 70 to 90 years between 2010 and 2015. Specifically, it focused on patients who underwent lumpectomy and omitted radiation
Hepatocellular Carcinoma Treatment Outcomes: The Influence Of Butyrate Producers
Hepatocellular Carcinoma Treatment Outcomes: The Influence Of Butyrate Producers Overview In a retrospective multi-center study involving 747 patients with advanced hepatocellular carcinoma (HCC) treated with a combination therapy of atezolizumab and bevacizumab, the influence of butyric acid-producing enterobacteria on treatment outcomes was investigated. Previous research has established a link between the gut
Control of Allergic Rhinitis and Asthma Test: A COSMIN Analysis
Control of Allergic Rhinitis and Asthma Test: A COSMIN Analysis Overview The Control of Allergic Rhinitis and Asthma Test (CARAT) serves as a patient-reported outcome measurement (PROM) to evaluate the management of asthma and allergic rhinitis (AR) within a 4-week timeframe. This systematic review aimed to assess CARAT's measurement properties. Adhering to
Tislelizumab Treatment And Quality Of Life In Lung Cancer Patients
Tislelizumab Treatment And Quality Of Life In Lung Cancer Patients Overview In the Phase 3 trial RATIONALE-303 (NCT03358875), the study evaluated the health-related quality of life (HRQoL) among patients with advanced non-small cell lung cancer (NSCLC) who were treated with either tislelizumab or docetaxel. The assessment utilized three measurement instruments: EORTC QLQ-C30,
